One-and 2-year evaluation of a feasibility trial (clinicaltrials.gov registration numbers NCT01057992, NCT01058070, and 01058564) to assess the safety and efficacy of a laparoscopically implanted sphincter augmentation device for the treatment of gastroesophageal reflux disease (GERD). Methods: A sphincter augmentation device (LINX Reflux Management System; Torax Medical, Shoreview, MN), designed to prevent reflux due to abnormal opening of the lower esophageal sphincter (LES), was laparoscopically implanted at the gastroesophageal junction in 44 patients. At baseline, all patients had abnormal esophageal acid exposure on 24-hour pH monitoring and improved, but persistent, typical GERD symptoms while on acid suppression therapy with proton pump inhibitors (PPIs). The device comprises a miniature string of interlinked titanium beads, with magnetic cores, placed around the gastroesophageal junction. The magnetic bond between adjacent beads augments sphincter competence. The beads temporarily separate to accommodate a swallowed bolus, allow belching or vomiting, and reapproximate to augment the LES in the closed position. Patients were evaluated after surgery by GERD Health-Related Quality of Life symptom score, PPI usage, endoscopy, esophageal manometry, and 24-hour esophageal pH monitoring. Results: The total mean GERD Health-Related Quality of Life symptom scores improved from a mean baseline value of 25.7 to 3.8 and 2.4 at 1and 2-year follow-up, representing an 85% and 90% reduction, respectively (P < 0.0001). Complete cessation of PPI use was reported by 90% of patients at 1 year and by 86% of patients at 2 years. Early dysphagia occurred in 43% of the patients and self-resolved by 90 days. One device was laparoscopically explanted for persistent dysphagia without disruption of the anatomy or function of the cardia. There were no device migrations, erosions, or induced mucosal injuries. At 1 and 2 years, 77% and 90% of patients had a normal esophageal acid exposure. The mean percentage time pH was less than 4 decreased from a baseline of 11.9% to 3.1% (P < 0.0001) at 1 year and to 2.4% (P < 0.0001) at 2 years. Patient satisfaction was 87% at 1 year and 86% at 2 years. Conclusions: The new laparoscopically implanted sphincter augmentation device eliminates GERD symptoms without creating undue side effects and is effective at 1 and 2 years of follow-up. FIGURE 1. A, The LINX in the closed position. B, The closed position showing no compression of the esophageal wall. C, The LINX in the open position.
population in Western countries and is the leading physician diagnosis in gastroenterology outpatient clinics. Acid suppression with proton pump inhibitors (PPIs) is the first-line therapy, but in almost 40% of patients, GERD-related symptoms persist despite high-dose medication. [1] [2] [3] Furthermore, it has been shown that patients with a mechanically defective lower esophageal sphincter (LES) are particularly difficult to maintain in a symptom-free state. They have nocturnal acid breakthrough, nonacid reflux, and can progress to complications of the disease such as position-related regurgitation with aspiration and Barrett metaplasia. 4, 5 These limitations of acid suppression therapy have encouraged the search for a more effective treatment by augmenting the LES rather than depending only on continuous suppression of gastric acid secretion. 6 Laparoscopic Nissen fundoplication can be used to treat these patients and is generally acknowledged to be an effective and durable therapy when performed by expert surgeons in specialized centers. 7 However, outside of such centers, the success rate varies widely. 8 Patients who have a Nissen operation are expected to accept a tradeoff between relief of GERD symptoms and the potential side effects of the procedure, namely, the inability to belch and vomit and the possibility of chronic dysphagia. 9 Consequently, gastroenterologists tend to limit their referrals for the Nissen procedure to patients with large hiatal hernia or advanced GERD.
The current treatment algorithm leaves a therapeutic gap of dissatisfied patients between those who are satisfied with their acid suppression therapy and those who had a Nissen fundoplication for advanced disease. The question emerges as to what is the best treatment of these "gap patients" who are dissatisfied with acid suppression therapy but remain reluctant to have a Nissen fundoplication because of concerns over the side effects of the procedure.
The LINX was developed to address this "therapy gap" with a simple standardized laparoscopic procedure that does not alter the anatomy of the cardia, provides relief of reflux-related symptoms without impeding the ability to belch or vomit, and is reversible if necessary. Importantly, the operation can be performed safely by surgeons by using standard laparoscopic techniques and instruments.
The intent of the LINX is to augment the barrier function of the LES. For reflux to occur through an augmented LES, gastric pressures must overcome both the patient's native LES pressure and the magnetic bonds of the device. Importantly, the device, while augmenting the LES, also expands to accommodate a swallowed bolus and allows belching or vomiting if needed. After laboratory testing in animals, 10 the device was approved for a clinical feasibility study in humans. The aim of this article was to report the 1-and 2-year results of this new device for the treatment of GERD. patients with GERD. The short-term results of this trial have already been reported. 11 The study protocol was approved by the ethical committee or institutional review board of the participating institutions. The trial was registered with clinicaltrials.gov (NCT01057992, NCT01058070, and 01058564). Each patient was informed about the investigational nature of the trial and received detailed information about the study protocol. A written informed consent was obtained before enrollment in the trial. The objectives of the present report were to evaluate the safety and efficacy of the device in humans after 1 and 2 years of implantation.
Patient inclusion criteria were as follows: age 18 years or older and younger than 85 years, typical reflux symptoms at least partially responsive to PPI therapy, abnormal esophageal acid exposure, and normal contraction amplitude and wave form in the esophageal body. Patients exclusion criteria were as follows: symptoms of dysphagia, previous upper abdominal surgery, previous endoluminal antireflux procedures, sliding hiatal hernia of 3 cm or more, greater than grade A esophagitis, and/or the presence of histologically documented Barrett esophagus.
Patient Population
A total of 44 patients had laparoscopic implantation of the LINX between February 2007 and October 2008. There were 26 (59%) men and 18 (41%) women (mean age: 42.3 years; range: 19-72 years). The body mass index ranged from 19.0 to 38.4 kg/m 2 (mean: 25.7). Heartburn was the primary symptom in all patients, and all patients were taking PPIs at standard or double dose for acid suppression. Eighteen patients had no hernia and 26 of the 44 patients (59.1%) had a less than 3-cm sliding hiatal hernia based on radiologic and/or endoscopic criteria.
Preoperative Assessment
Each patient was evaluated before surgery with a symptom questionnaire, upper gastrointestinal endoscopy, barium swallow, esophageal manometry, and 24-hour esophageal pH monitoring. The Gastro-Esophageal Reflux Disease Health-Related Quality of Life (GERD-HRQL) questionnaire 12 was administered preoperatively "off" PPI therapy before any diagnostic test. This validated questionnaire consists of 6 heartburn-related questions, 3 swallowrelated questions, 1 gas bloating question, and 1 question related to medication use. The responses to these questions are scored according to definitions given in Table 1 .
Upper gastrointestinal endoscopy was performed to assess the presence of esophagitis, using the Los Angeles or Savary-Miller classification. The length of hiatal hernia, if present, was measured as the distance between the gastroesophageal junction (GEJ), defined by the proximal limit of the gastric folds, and the crural impression.
Esophageal manometry was used to measure LES pressure and length with a station pull-through technique. The degree of LES relaxation was assessed with 5 wet swallows. Esophageal contractility was assessed with 10 wet swallows of 5 mL each, taken 30 seconds apart. Symptoms affect daily activities 5
Symptoms are incapacitating; unable to do activities Abnormal motility was defined as mean contraction amplitude of 30 mmHg or less and/or a more than 30% prevalence of simultaneous, dropped, or interrupted waves. Twenty-four hour esophageal pH monitoring was performed "off" PPI therapy by placing the pH probe or capsule 5 cm above the upper border of the LES determined by manometry or 6 cm above the Z-line determined by endoscopy. Abnormal esophageal acid exposure was verified before implantation.
Features of the Sphincter Augmentation Device
The LINX consists of a series of titanium beads with magnetic cores hermetically sealed inside. The beads are interlinked together with independent titanium wires to form a flexible ring that rests around the LES in a circular fashion (Fig. 1A) . The strength of the magnetic core contained in each bead is designed by mass to augment the ability of the sphincter to resist opening from gastric pressures. The augmentation force provided by the device is permanent. When implanted all the beads are touching each other to ensure no compression of the esophageal wall (Fig. 1B) . The magnetic bond between beads is easily broken by the transport force of a swallowed bolus, allowing the beads to separate and a food bolus to freely pass (Fig. 1C ). The attraction force between magnets exponentially reduces with the separation distance. The device is capable of nearly doubling its diameter when all beads are separated. Unique to the design is that the magnetic attraction force that must be overcome to allow separation of the beads is the same regardless of the number of beads contained in the device (Fig. 2) .
The device is manufactured in different lengths based on the number of beads necessary to accommodate the varied esophageal circumferences. The smallest and largest configurations consist of 10 to 18 beads. Before implantation, the device is sized specifically to the circumference of the patient's esophagus, using a special measuring tool that is wrapped around the esophagus at the GEJ to select the appropriate size of the implant (Fig. 3 ).
Surgical Technique
The device is implanted laparoscopically under general anesthesia. The visceral peritoneum on the anterior surface of the esophagogastric junction is divided to expose the anterior esophageal wall. The anterior vagal trunk is identified, but no attempt is made to dissect it from its intramuscular location. The hepatic branch of the anterior vagus nerve is preserved (Fig. 4a ). The retroesophageal dissection begins along the anterior border of the right crus just cephalad to decussation of the crura. The posterior vagal trunk is identified (Fig. 4b) .
The same dissection is repeated along the left crus of the diaphragm. Gentle dissection from the right opens the retroesophageal window, and a tunnel is created between the posterior esophageal wall and the posterior vagal trunk. A 6-mm Penrose drain is passed through the retroesophageal window to encircle the esophagus. The sizing tool is passed through the posterior esophageal tunnel and wrapped around the esophagus above the hepatic branch of the anterior vagal trunk. The appropriate size of the LINX is passed through the tunnel, wrapped around the esophagus proximal to the hepatic branch of the anterior vagus nerve, and laid in the incision created in the visceral peritoneum over the anterior surface of the GEJ. The sutures at both ends of the device are secured with a Ti-Knot (LSI Solutions, Victor, NY). The target location of the device is the endoscopic Z-line. Posterior cruroplasty was added to the procedure in 5 patients. 
Postoperative Assessment
Initial position and function of the device were verified with a standard chest radiograph and a modified barium esophagram obtained the day after implantation before hospital discharge. The GERD-HRQL questionnaire, upper gastrointestinal endoscopy, modified barium esophagram, and 24-hour esophageal pH monitoring were obtained at 3 months and at 1 and 2 years after surgery. Esophageal manometry was obtained at 3 months and 1 year. 
RESULTS
All devices were implanted laparoscopically without operative complications. The median operative time was 40 minutes (range: 19-104). A free diet was allowed after radiological assessment of esophageal transit on postoperative day 1. All but 1 patient was discharged within 48 hours. Mild dysphagia was present in 43% of patients during the postoperative period, and it resolved by 90 days without treatment.
The median number of days since implantation was 895 days (range: 226-1144). To date, 40 of the 44 implanted patients have completed their clinical and pH-metry assessment at either 1 or 2 year pH follow-up. Two patients were explanted, 1 at 8 months because of persistent dysphagia and the other at 18 months because of the need for a magnetic resonance imaging (MRI) study. Two patients withdrew consent, and 1 subject is lost to follow-up.
Clinical Evaluation
The mean GERD-HRQL score at 1 year, when compared with the baseline score, decreased by 85% and at 2 years by 90% (P < 0.0001) ( Fig. 5) . Changes in the specific components of the GERD-HRQL score are shown in Table 2 . At 1 and 2 years, 90% and 86% of the patients were completely "off" PPI therapy. A post hoc question- naire showed that all patients maintained their ability to belch; in addition, 4 patients experienced the need to vomit and were able to do so.
Barium Swallow
The day after surgery the device was seen positioned just below the diaphragm in 42 patients and 1 to 2 cm above the diaphragm in 2 patients. Both of these patients had a less than 3-cm hiatal hernia before surgery that was not repaired. It is likely that the device in both patients was within the hernia sac. No device migration occurred during the follow-up period.
Endoscopy
On upper gastrointestinal endoscopy, the impression of the device was observed in the region of the GEJ in all patients. There was no increased resistance to passage of a standard 9-mm endoscope. To date, no mucosal or transmural erosions of the device have been reported.
Esophageal Manometry
Thirty-two patients had both baseline and 1-year postoperative manometric testing available for comparison. Lower esophageal sphincter resting pressure increased from 6.5 to 14.6 mmHg (P < 0.005) in 9 patients with hypotensive (<10 mmHg) LES pressure. In 23 patients with normal LES pressure at baseline, no significant changes in pressure occurred (baseline = 18.1 mmHg, postoperative = 19.7 mmHg). There were no statistically significant changes in the overall or abdominal length of the LES. Similarly, there were no statistically significant changes in the amplitude of esophageal contractions.
Twenty-Four-Hour Esophageal pH Monitoring
The esophageal acid exposure was normalized for the total time in 77% and 90% of patients at 1 and 2 years, respectively (Fig. 6) . The mean percentage time pH was less than 4, which decreased from a preoperative baseline of 11.9% to 3.1% at 1 year and 2.4% at 2 years. All the other components of the 24-hour pH test and the DeMeester composite score were significantly reduced compared with baseline at 1 and 2 years (Table 3) . years ago Rudolf Nissen introduced the Nissen fundoplication. Today, the procedure can be performed successfully by laparoscopy. Despite this, its use has been resisted by gastroenterologists because of the variability in outcomes, the risks of new side effects, and the degree of anatomical distortion associated with the operation. These limitations are also of concern to patients with uncomplicated disease who are dissatisfied with the relief they obtain from acid suppression therapy but are reticent to accept surgical therapy because of the potential side effects of a fundoplication. For the most advanced GERD patients, the benefits of the Nissen procedure generally outweigh its side effects. Partial fundoplication procedures have been proposed as suitable alternatives to reduce the side effects of the Nissen operation, but this concept has not been proven in randomized clinical trials. Existing literature from experienced centers does not clearly confirm a significant reduction of side effects while maintaining objective evidence of reflux control. 13, 14 The LINX device was developed to provide a less variable procedure with less anatomical alteration allowing reversibility if necessary and afford with a better trade-off between clinical effectiveness and the potential side effects. It was designed specifically for patients with uncomplicated disease who are dissatisfied with their acid suppression therapy.
Migration and erosion of the device have not occurred to date. It is likely that the miniature size of the LINX, its "Roman arch" design, and its dynamic properties allow it to mimic the physiologic motion of the esophageal wall, thereby minimizing the likelihood of tissue injury or erosion. Long-term evaluation is needed to confirm this theory. Currently, MRI is contraindicated after LES augmentation with the LINX. Further testing is planned to evaluate the interaction between the LINX and MRI. Implantation of the LINX requires minimal surgical dissection with preservation of normal anatomy. In most patients, a distinct phrenoesophageal ligament was identified and preserved. 15 This, combined with the creation of a tunnel between the posterior wall of the esophagus and the posterior vagus nerve, provided a safe and proper anchoring berth for the LINX and prevented its migration. In patients with less than 3-cm hiatal hernia, downward traction of the proximal stomach and the application of positive end-expiratory pressure help to expose the phrenoesophageal ligament and the posterior vagus nerve.
The efficacy of the LINX design has been confirmed in animals and now in human feasibility trials. The mechanism is based on using the force of magnetic attraction to augment the resistance of the LES to gastric distention. The precise sizing of the device with the beads approximated to match the outer diameter of the resting GEJ prevents compression of the esophagus while increasing its resistance to opening by gastric distension or pressure. [16] [17] [18] This concept is supported by the observation that the device did not significantly alter the resting LES pressure in those patients who had a normal LES pressure before surgery.
All patients in this series had the ability to belch after surgery. Dysphagia was observed during the initial postoperative period in less than half of the patients, even though they were given a solid food diet on the first postoperative day. The procedure is truly reversible in that 2 patients had an uneventful laparoscopic removal of the device without disrupting the anatomy of the cardia. Months later 1 patient went on to have laparoscopic Nissen fundoplication. Tissue scarring at the GEJ was minimal and did not increase the difficulty of the surgical procedure.
The simple and standardized technique for insertion, and the minimal surgical dissection required to place the LINX, will likely allow for a more consistent and less variable outcome in the surgical control of reflux. Furthermore, the short operating time and the ability to take a normal diet the day after implantation of the device make this procedure suitable for outpatient surgery.
In conclusion, the 1-and 2-year follow-up study of the sphincter augmentation device LINX showed excellent relief from GERD symptoms and significantly reduced esophageal acid exposure without creating new side effects. 
DISCUSSION

DISCUSSANTS T. Lerut (Leuven, Belgium)
While we are aware that in experienced hands the laparoscopic Nissen antireflux procedure provides 90% reflux control, there is at least a 6% redo rate and, as you indicated, perhaps a less well-defined incidence of undesired disabling side effects in some patients. This is certainly one of the reasons that our nonsurgical colleagues, together with the medical industry, have been looking for nonsurgical procedures to possibly increase the already good results they can obtain through medical treatment with PPI. The development of Oesophix is one of such example of an endoscopic approach. Within this context, I believe this sphincter augmentation technique is a timely and very original contribution supported by experimental data.
As far as I understand from the article, your indications relate to a very selective group of hernias, those less than 3 cm, without motor disorders, and without Barrett. In fact, your group of patients represents only a small minority of the patients that are referred for laparoscopic antireflux procedures, and that may be a very limiting factor. What prevents you from expanding the indications for surgery?
A second point relates to the safety issue. I am not sure that you can conclude this is safe with a follow-up period of only 2 years. Indeed, I must remind you of what occurred with the Angelchik prosthesis, in which we saw an increasing number of intrathoracic migrations, erosions, and so on, in late follow-up. Are you sure that the safety issue is really solved?
Just a practical question, can those patients have an MRI or can they go through the airport control systems without triggering the alarm? Finally, I would think that your study is asking to be followed by a randomized control trial. My question is: If you do a randomized control trial, would you do it against Oesophix, laparoscopic Nissen, or both?
Response From L. Bonavina
This new procedure is intended to fill the existing therapeutic gap between patients satisfied with PPI treatment and those who are reluctant to undergo Nissen fundoplication. I agree that the laparoscopic Nissen fundoplication is the gold standard, but it has been shown that the results of this procedure are suboptimal in the community setting. This is in part because the Nissen procedure is a complex operation and requires an expert surgeon. Going to the specific questions, it is true that our patient sample is not representative of the entire GERD population, but this was a feasibility study. We did not want to mix up the effect of crural repairs with the effect of the device itself. Regarding the safety issue, the design of this device is completely different from the Angelchik prosthesis, which was a fixed, rigid band of about 50 mL in volume. The LINX is a flexible device that complies with esophageal motion and distension and is only 1.2 mL in volume. With time this design premise will be further validated; so far, at 2 years of follow-up, there was no endoscopic evidence of tissue injury or migration. Regarding the MRI issue, this device has been tested in the laboratory with 1.5-T equipment and no problems were encountered. Further testing is indeed needed and is planned. No problems related to airport travel have been reported. The last question relates to the possibility of a randomized control trial. I think that a study comparing the LINX with either PPI therapy or with Toupet fundoplication could be conducted in the future to evaluate which procedure is associated with fewer side effects while maintaining reflux control.
DISCUSSANTS
J. Hunter (Portland, OR)
One of your hypotheses indicates that this procedure is standardized and can be performed by surgeons without great expertise. How do you plan to prove this hypothesis?
Response From L. Bonavina
The learning curve for this procedure is different and simpler than for Nissen fundoplication because the fundus is not dissected, it takes less time, and is less subject to variability. It is important, however, to rely on a competent esophageal surgeon. Potentially, a more standardized result will be obtained. This hypothesis should be further demonstrated in additional trials by showing that outcomes are not center or surgeon dependent. Currently, a trial with 15 centers was conducted in Europe and the United States, including both academic and community hospitals. The results of this trial should be available in 2011.
